3月24日，美国食品与药物管理局（FDA）警告，抗心律失常药物胺碘酮与丙肝抗病毒治疗药物ledipasvir/sofosbuvir（Harvoni）或sofosbuvir（Sovaldi）同时应用时可导致患者症状性心动过缓。该警告内容将会被加入相应药物的说明书中。FDA也将继续调查这种心脏事件的原因。

    信息原文：

    FDA Warns Against Combination of Hepatitis C Treatment and Antiarrhythmic Drug | ACC News StoryOn March 24, the U.S. Food and Drug Administration （FDA） issued a warning against taking the antiarrhythmic drug amiodarone in combination with hepatitis C drug treatments and another direct acting antiviral.

    In their announcement, the FDA stated that amiodarone “taken together with either the hepatitis C drug Harvoni （ledipasvir/sofosbuvir） or with Sovaldi （sofosbuvir）， taken in combination with another direct acting antiviral for the treatment of hepatitis C infection” can cause symptomatic bradycardia. The warning will be added to the labels of Harvoni and Sovaldi, and the FDA will continue to investigate the cause of the heart-related events.